Total Payments
$160,644
2024 Payments
$18,147
Companies
17
Transactions
130
Medicare Patients
949
Medicare Billing
$200,328
Payment Breakdown by Category
Consulting$103,008 (64.1%)
Other$38,543 (24.0%)
Travel$13,087 (8.1%)
Food & Beverage$3,802 (2.4%)
Research$2,204 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $103,008 | 40 | 64.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,643 | 9 | 23.4% |
| Travel and Lodging | $13,087 | 34 | 8.1% |
| Food and Beverage | $3,802 | 45 | 2.4% |
| Unspecified | $2,204 | 1 | 1.4% |
| Honoraria | $900.00 | 1 | 0.6% |
Payments by Type
General
$158,440
129 transactions
Research
$2,204
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59,378 | 45 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $29,629 | 21 | $0 (2024) |
| Eli Lilly and Company | $23,633 | 7 | $0 (2020) |
| Lilly USA, LLC | $12,040 | 12 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $8,410 | 9 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $6,113 | 6 | $0 (2024) |
| AstraZeneca UK Limited | $5,973 | 9 | $0 (2021) |
| Amgen Inc. | $4,800 | 3 | $0 (2020) |
| Genentech, Inc. | $3,504 | 5 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $2,395 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,147 | 19 | Regeneron Pharmaceuticals, Inc. ($8,410) |
| 2023 | $23,750 | 9 | Merck Sharp & Dohme LLC ($23,639) |
| 2022 | $8,740 | 2 | Merck Sharp & Dohme LLC ($6,100) |
| 2021 | $16,566 | 6 | Taiho Oncology, Inc. ($6,250) |
| 2020 | $13,741 | 8 | Eli Lilly and Company ($5,950) |
| 2019 | $13,896 | 23 | Merck Sharp & Dohme Corporation ($7,482) |
| 2018 | $39,643 | 38 | Eli Lilly and Company ($10,533) |
| 2017 | $26,161 | 25 | Merck Sharp & Dohme Corporation ($10,659) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| 12/31/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $302.50 | General |
| 12/31/2024 | TAIHO ONCOLOGY, INC. | — | Travel and Lodging | Cash or cash equivalent | $132.66 | General |
| 10/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 09/30/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| 09/16/2024 | Astellas Pharma Inc | — | Food and Beverage | In-kind items and services | $50.66 | General |
| 07/31/2024 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| 07/31/2024 | TAIHO ONCOLOGY, INC. | — | Food and Beverage | Cash or cash equivalent | $157.30 | General |
| 06/17/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| 06/01/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $133.98 | General |
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,562.00 | General |
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $927.00 | General |
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $695.25 | General |
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 01/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $123.44 | General |
| 01/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $60.55 | General |
| 01/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $60.36 | General |
| 01/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $54.55 | General |
| 09/25/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 08/30/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 06/09/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/02/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,150.00 | General |
| 05/20/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $5,148.59 | General |
| 05/20/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $341.57 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| P3 Gastric Asian MRCT | Amgen Inc. | $2,204 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 263 | 721 | $380,465 | $56,123 |
| 2022 | 5 | 266 | 659 | $344,030 | $52,542 |
| 2021 | 3 | 217 | 622 | $321,225 | $50,349 |
| 2020 | 4 | 203 | 669 | $304,775 | $41,314 |
Total Patients
949
Total Services
2,671
Medicare Billing
$200,328
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 408 | $222,360 | $32,509 | 14.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 224 | $84,000 | $11,967 | 14.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 53 | 53 | $55,385 | $7,814 | 14.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 36 | $18,720 | $3,833 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 338 | $184,210 | $27,693 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 87 | 206 | $77,250 | $11,801 | 15.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 55 | 55 | $57,475 | $8,842 | 15.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 39 | $20,475 | $3,622 | 17.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 11 | 21 | $4,620 | $582.83 | 12.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 79 | 316 | $172,220 | $27,006 | 15.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 87 | 255 | $95,625 | $14,805 | 15.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 51 | 51 | $53,380 | $8,537 | 16.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 333 | $173,160 | $22,560 | 13.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 80 | 266 | $94,430 | $12,408 | 13.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 31 | 31 | $30,690 | $4,480 | 14.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 14 | 39 | $6,495 | $1,866 | 28.7% |
About Dr. David Ilson, MD
Dr. David Ilson, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720181696.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Ilson, MD has received a total of $160,644 in payments from pharmaceutical and medical device companies, with $18,147 received in 2024. These payments were reported across 130 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($103,008).
As a Medicare-enrolled provider, Ilson has provided services to 949 Medicare beneficiaries, totaling 2,671 services with total Medicare billing of $200,328. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location New York, NY
- Active Since 09/06/2006
- Last Updated 04/06/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1720181696
Products in Payments
- Lonsurf (Drug) $13,414
- CYRAMZA (Drug) $9,709
- KEYTRUDA (Biological) $4,107
- Avastin (Biological) $3,547
- IMFINZI (Drug) $2,395
- OPDIVO (Biological) $2,306
- Vitrakvi (Drug) $1,970
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M